{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin-to-skin&page=4",
    "query": {
      "condition": "Skin-to-skin",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 6423,
    "total_pages": 643,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin-to-skin&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin-to-skin&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T15:07:18.687Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06439667",
      "title": "Tele-Exercise Platform for Plantar Wound Healing",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetic Foot Ulcer",
        "Wound Healing",
        "Wound Care"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2025-12-15",
      "completion_date": "2026-05-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-10-09T15:07:18.687Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06439667"
    },
    {
      "nct_id": "NCT06425900",
      "title": "A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Winlevi (Clascoterone) cream 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 10,
      "start_date": "2024-07-01",
      "completion_date": "2026-03",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-10-09T15:07:18.687Z",
      "location_count": 1,
      "location_summary": "High Point, North Carolina",
      "locations": [
        {
          "city": "High Point",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06425900"
    },
    {
      "nct_id": "NCT04583007",
      "title": "Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Hereditary Angioedema (HAE)",
        "Angioedema"
      ],
      "interventions": [
        {
          "name": "Lanadelumab 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Lanadelumab 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2023-07-24",
      "last_synced_at": "2026-10-09T15:07:18.687Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 10 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04583007"
    },
    {
      "nct_id": "NCT00002144",
      "title": "The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Herpes Simplex",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Foscarnet sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astra USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 12,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-09T15:07:18.687Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002144"
    },
    {
      "nct_id": "NCT06624644",
      "title": "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Melanoma (Skin Cancer)",
        "Melanoma Stage IIIB-IV",
        "Cutaneous Melanoma",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "LNS8801",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy (dacarbazine or temozolomide)",
          "type": "DRUG"
        },
        {
          "name": "Immunotherapy (Pembrolizumab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immunotherapy (nivolumab and relatlimab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immunotherapy (ipilimumab and nivolumab)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Linnaeus Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2025-08-06",
      "completion_date": "2031-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-10-09T15:07:18.687Z",
      "location_count": 9,
      "location_summary": "Newport Beach, California • San Francisco, California • Stanford, California + 6 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06624644"
    },
    {
      "nct_id": "NCT00769184",
      "title": "Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Corticosteroid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "LCD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NeoStrata Company, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2008-10",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2015-08-19",
      "last_synced_at": "2026-10-09T15:07:18.687Z",
      "location_count": 1,
      "location_summary": "East Windsor, New Jersey",
      "locations": [
        {
          "city": "East Windsor",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00769184"
    },
    {
      "nct_id": "NCT02189278",
      "title": "Improving Adherence to Recommended Surveillance in Breast Cancer Survivors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Psychosocial Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "21 Years and older · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2013-10",
      "completion_date": "2017-06-12",
      "has_results": false,
      "last_update_posted_date": "2018-10-03",
      "last_synced_at": "2026-10-09T15:07:18.687Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02189278"
    },
    {
      "nct_id": "NCT01577550",
      "title": "Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "BI 655066 (very high i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo, i.v.",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (high s.c. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (low i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (high medium i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (very low i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (low s.c. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (high i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo, s.c.",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (low medium i.v. dose)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 39,
      "start_date": "2012-04",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2016-11-16",
      "last_synced_at": "2026-10-09T15:07:18.687Z",
      "location_count": 7,
      "location_summary": "Burbank, California • Miami, Florida • Port Orange, Florida + 4 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01577550"
    },
    {
      "nct_id": "NCT03421197",
      "title": "A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "PPC-06 400 mg QD",
          "type": "DRUG"
        },
        {
          "name": "PPC-06 400 mg BID",
          "type": "DRUG"
        },
        {
          "name": "PPC-06 600 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Reddy's Laboratories Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 426,
      "start_date": "2018-01-25",
      "completion_date": "2020-03-30",
      "has_results": true,
      "last_update_posted_date": "2022-04-01",
      "last_synced_at": "2026-10-09T15:07:18.687Z",
      "location_count": 74,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 54 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Bryant",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03421197"
    },
    {
      "nct_id": "NCT00005610",
      "title": "Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2000-09",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2016-07-13",
      "last_synced_at": "2026-10-09T15:07:18.687Z",
      "location_count": 18,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Cedar Rapids",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005610"
    }
  ]
}